For Hyundai Elantra 2011-2016 Walker 52597 Aluminized Steel Exhaust Front Pipe Car & Truck Exhaust Pipes & Tips


  1. Home
  2. For Hyundai Elantra 2011-2016 Walker 52597 Aluminized Steel Exhaust Front Pipe
  1. facebook
  2. twitter
  3. linkedin
  4. pinterest
For Hyundai Elantra 2011-2016 Walker 52597 Aluminized Steel Exhaust Front Pipe
Condition: New Brand:

Walker

Material: Aluminized Steel Manufacturer Part Number:

52597

Product Details: Exhaust Front Pipes Other Part Number: 2265104147
Department: Replacement Product Type: Replacement Exhaust Parts
Product Name: Exhaust Front Pipe Product SubType: Exhaust Pipes
Fitment Type: Direct Replacement UPC:

086387525978



published on tue nov 09 2021

For Hyundai Elantra 2011-2016 Walker 52597 Aluminized Steel Exhaust Front Pipe Car & Truck Exhaust Pipes & Tips

gandhi, s., klein, j., robertson, a., pena-hernandez, m. a.,

For Hyundai Elantra 2011-2016 Walker 52597 Aluminized Steel Exhaust Front Pipe Car & Truck Exhaust Pipes & Tips

lin, m. j., roychoudhury, p., lu, p., fournier, j., ferguson, d., mohamed bakhash, s. a., muenker, m. c., srivathsan, a., wunder, e. a., kerantzas, n., wang, w., pyle, a., wilen, c. b., ogbuagu, o., greninger ,, a. l., iwasaki, a., schulz, w. l., ko, a. i.

sars-cov-2 remdesivir resistance mutations have been generated in vitro but have not been reported in patients receiving treatment with the antiviral agent. we present a case of an immunocompromised patient with acquired b-cell deficiency who developed an indolent, protracted course of sars-cov-2 infection. remdesivir therapy alleviated symptoms and produced a transient virologic response, but her course was complicated by recrudescence of high-grade viral shedding. whole genome sequencing identified a mutation, e802d, in the nsp12 rna-dependent rna polymerase which was not present in pre-treatment specimens. in vitro experiments demonstrated that the mutation conferred a ~6-fold increase in remdesivir ic50 but resulted in a fitness cost in the absence of remdesivir. sustained clinical and virologic response was achieved after treatment with casirivimab-imdevimab. although the fitness cost observed in vitro may limit the risk posed by e802d,

, this case illustrates the importance of monitoring for remdesivir resistance and the potential benefit of combinatorial therapies in immunocompromised patients with sars-cov-2 infection.

509
1.2k
EVGENIA.RU RSS